Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Kr�� Janez) .

11 - 20 / 497
First pagePrevious page12345678910Next pageLast page
11.
12.
What is the most common mammographic appearance of T1a and T1b invasive breast cancer?
Maja Podkrajšek, Janez Žgajnar, Marko Hočevar, 2008, original scientific article

Published in DiRROS: 07.03.2024; Views: 69; Downloads: 19
.pdf Full text (204,48 KB)

13.
14.
15.
Preoperative concomitant chemoradiotherapy in esophageal cancer
Boštjan Šeruga, Mihael Sok, Janez Eržen, Jože Jerman, Boris Jančar, Branko Zakotnik, 2006, original scientific article

Abstract: Background. Currently primary treatment options for esophageal cancer are surgery only or concomitant chemoradiotherapy (CRT) and the long-term survivalof patients with locally advanced disease is rare. Preoperative concomitant CRT seems to be beneficial, mostly in patients who achieve a complete pathologic response (pCR) after CRT. In this retrospective analysis the efficiency and toxicity of preoperative CRT in patients with locally advanced esophageal cancer was analysed as well as the influence of pCR on thesuraival. Patients and metkods From 1996 to 2002 41 patients with locoregionally confined esophageal cancerwere treated with cisplatin 75 mgžm2 and 5-FU 1000 mgžm2 as 4 day contonuous infusion starting on days 1. and 22. with concorrtitant radiotherapy 4500 cGy, 200-300 cGyžday. Esophagectomy followed 4-5 weeks after radiotherapy. After the surgery patients were followed-up regularly at 3-6 months intervals. Results. The pCR was achieved in 26.8% of patients. The overall median survival time was 18 months for all patients, 21.2 months for patients who achieved pCR and 16 months in those with residual disease (p= 0,79). Postoperative mortality rate was 22%. The median dose intensity for cisplatin was 92% and for 5-FU 71.5 of the planned dose. Disease recurred most often locoregionally (31.7%) and the overall recurrence rate was 43.9. Conclusion. Modern radiation techniques and the adequate dose intensity could further improve the locoregional control. The selection of patients without comorbid conditions and without already present distant metastases is essential for this combined treatment approach.
Published in DiRROS: 15.02.2024; Views: 100; Downloads: 25
.pdf Full text (123,83 KB)

16.
Surgical treatment of malignant pleural mesothelioma
Janez Eržen, Stanko Vidmar, Mihael Sok, Andrej Debeljak, Peter Kecelj, Viljem Kovač, Marjeta Stanovnik, Tomaž Rott, Izidor Kern, 2005, original scientific article

Abstract: Background. The aim of the study was to identify perioperative morbidity and mortality, the category and mode of adjuvant treatment, local recurrence and survival in patients treated by extrapleural pneumonectony (EPP) for malignantpleural mesothelioma (NLPM). Methods. From 2000 to 2003, 18 patients with MPM were referred to the Department of Thoracic Surgery in Ljubljana, and17 of them were operated on. Two patients underwent explorative thoracotomy, and 15 patients were evaluated. Five female and nine male patients (aged 52-68 years) were treated by EPP and one male patient by pleurectomy. Eight patients received both adjuvant chemotherapy (ChT) and radiotherapy (RT), with cisplatin 100 mg/m2 + mitomycin C 6-10 mg/m2 gemcitabine 1000 mg/m2 and external beam radiation with 24 Gy - 58 Gy respectively, three patients received no adjuvant therapy, three patients weretreated by adjuvant ChT, two of them were given cisplatin 100 mg/m2 + mitomycin C 6-10 mg/m2, and one patient cisplatin 100 mg/m2 on the first day and gemcitabine 250 mg/rn2 in prolonged 6 hours infusion on the first and on the eighth day. One patient was treated only by adjuvant RT. Results. There were no perioperative deaths and the postoperative morbidity was 42%. Of the 15 evaluable patients, and in the median follow up of 40 months (28-64), we noticed nine (60.0%) recurrences, seven local and two abdominal. Eight (53.3%)patients died, all because of the local progress of disease. (Abstract truncated at 2000 characters)
Published in DiRROS: 14.02.2024; Views: 123; Downloads: 29
.pdf Full text (82,10 KB)

17.
Characterization of lung cancer patients, their actual treatment and survival : experience of Slovenia
Lučka Debevec, Andrej Debeljak, Janez Eržen, Viljem Kovač, Izidor Kern, 2005, original scientific article

Abstract: Background. The aim of the study was to establish characteristics of lung cancer patients diagnosed at the University Clinic of Respiratory and AllergicDiseases Golnik in 1996, their selected and realized therapy, and survival. Methods. The retrospective study comprises 345 patients aged from 37to 90 years (mean 65), 285 males and 60 females. Performance status (Karnofsky): > 80 in 171 patients, 60-80 in 130 and < 60 in 44 patients. Mirroscopically confirmed tumour in 97%: by bronchoscopy 281, transthoracic needle biopsy 23, peripheral lymph nodes biopsy 12, sputum cytology 7, pleural(effusion) cytology 4, distant metastases biopsy 2, mediastinoscopy 1, autopsy 4 patients. Histology and/or cytology: squamous 131, adenocarcinoma 86, large cell 63, small cell 51, non-small cell 1, unclassified 2. Clinical staging of non-small cell lung cancer (NSCLC): stage I 63, stage ll 32, stage IIIA 48, stage IIIB 59, stage IV 77, undeterminable 2 patients. Staging in small cell lung cancer (SCLC): limited disease 24, extended disease 27 patients. Results. The selected primary oncological therapy was changed in 11%. Realized primary therapy: radiotherapy 102 (30%), surgery 77 (23%), chemotherapy 47 (14%), supportive treatment 111 (33%). In resected patients staging was correct in 46%, underestimated in 44%, overestimated in 10%. The overall five-year survival was 7.8% (median 6.2 months) and the five year survival of resected patients was 41.9% (median 33 months). The median survival of irradiated patients was 5.7 months, of supportively treated patients 2.5 months. The survival was significantly different according to theperformance status and stage. (Abstract truncated at 2000 characters)
Published in DiRROS: 14.02.2024; Views: 95; Downloads: 23
.pdf Full text (88,13 KB)

18.
Radioactive sources in brachytherapy
Janez Burger, 2003, professional article

Abstract: Background. In modern brachytherapy, a greast step forward was made in the 1960s in France with the introduction of new radioactive isotopes and new techniques. These innovations spread rapidly across Europe, though no single dosimetry standard had been set by then. In the new millennium, the advances in brachytherapy are further stimulated by the introduction of 3-D imaging techniques and the latest after loading irradiation equipment that use point sources. The international organiyation ICRU (International Commission on Radiation Units) worked out brachytherapy techniques and standardized them in 1985 and in 1997. Due to rapid development of new techniques, the revision is required in order to set new international standards in dosimetry and brachytherapy techniques that will fit to the changed conditions in radiotherapy. Conclusions. This is an outline of radioactive sources that are currently used in brachytherapy, such as Cs-137, Ir-192, Ra-226, Rn-222, Co-60, I-131, I-125, Pd-103, Tu-106 and Cf-252.
Published in DiRROS: 06.02.2024; Views: 114; Downloads: 26
.pdf Full text (96,64 KB)

19.
Quantifying the environmental implication of cotton-fiber-based nanocrystalline cellulose : a life-cycle assessment
Katja Malovrh Rebec, Janez Turk, Matjaž Kunaver, 2024, original scientific article

Abstract: Considering the increasing demand for nanocrystalline-cellulose in the industry, due to its exceptional physical and biological properties, cheaper and more efficient production processes are sought. Addressing environmental concerns, especially within the framework of EU policies, this study employs Life Cycle Assessment (LCA) to evaluate the environmental performance of a novel nanocrystalline-cellulose production procedure, encompassing biomass depolymerization, rinsing, and bleaching. The LCA aims to identify environmental hotspots, explore mitigation measures, and enables comparisons with other LCA studies on nanocrystalline-cellulose. The results are calculated and reported for 19 environmental impact categories, using the ReCiPe 2016 impact assessment method. The production of 1 kg of dry nanocrystalline-cellulose using the novel process emits 63.7 kg CO2 equivalent, which is lower than the literature average (68 kg CO2 equivalent). The solvent (e.g. diethylene glycol) is the major contributor to the global warming potential and fossil-fuel depletion potential in the product stage of the nanocellulose, while the electricity requirements and glycerin represent environmental hotspots regarding 15 of the 19 impact categories assessed. In terms of the water-consumption potential, the environmental hotspot is production of raw materials (e.g. cotton fibers). Electricity contributes more than 50 % of the burden to the impact categories associated with ionizing radiation, the pollution of aquatic ecosystems and human toxicity related to cancer. It also holds a significant share of the burdens for terrestrial acidification (48 % of the impact), the formation of fine particulate matter (46 % of the impact), and human toxicity related to non-cancer diseases (37 % of the impact). This underscores the importance of optimizing the production process, possibly through upscaling. Additionally, incorporating on-site renewable energy sources and utilizing biomass-derived diethylene glycol can enhance the environmental performance of nanocrystalline-cellulose.
Keywords: LCA, cascade use, cellulose nanocrystals, pilot production, environmental performance
Published in DiRROS: 06.02.2024; Views: 104; Downloads: 59
.pdf Full text (5,07 MB)
This document has many files! More...

20.
Cysteine proteinase inhibitors stefin A and stefin B in operable carcinoma of the head and neck : Inhibitorji cisteinskih proteinaz stefin A in stefin B pri operabilnem karcinomu glave in vratu
Primož Strojan, Marjan Budihna, Alojz Šmid, Branka Svetic, Ivan Vrhovec, Janko Kos, Janez Škrk, 2002, original scientific article

Abstract: Purpose. To evaluate the significance of cysteine proteinase inhibitors stefins (Stefs) A and B for a treatment decision and prognosis in operable squamous cell carcinoma of the head and neck (SCCHN). Patients and methods. Stefs A and B concentrations were determined immunobiochemically using ELISAs in cytosols prepared from the tumor and adjacent normal mucosa from 91 patients with operable SCCHN. The median follow-up period of patients alive atthe close-out date was 5.8 years (range, 5-9.3 years). Results. Stef A concentrations were significantly higher in tumor compared to normal mucosa (FM.05). When a subgroup with clinically palpable nodes) at presentation was taken into consideration (n=57), a significant difference in Stef A (P=0.03) and Stef B (P=0.02) concentrations between those with negative and positive necks, as determined on histopathological examination, was observed. On the univariate survival analysis, higher Stefsć concentrations turned to be prognostically advantageous. Stef A proved its independent prognostic significance also on multivariate setting. Conclusions. With the capability todifferentiate between the pN0- and pN+-stages of the disease in the patientsoriginally presented as node-positive, Stefs A and B could be useful markers when deciding on the extent of neck surgery. In addition, both Stefs proved to be reliable prognosticators for survival in patients with operable SCCHN.
Published in DiRROS: 31.01.2024; Views: 119; Downloads: 29
.pdf Full text (114,91 KB)

Search done in 0.28 sec.
Back to top